Melbourne: Orica (ASX: ORI) Chairman Malcolm Broomhead today announced the appointment of Mr Gordon Naylor as independent, non-executive Director, effective 1 April 2022.
Mr Broomhead said that with Mr Naylor’s many years of global leadership experience at CSL, he will be a strong addition to the Board and complement the future strategy of the company.
“I am delighted to welcome Gordon to the Orica Board. He is an experienced business leader with a strong track record in growing businesses in challenging international environments. With his engineering background, and experience in global supply chain and information systems strategy and implementation, Gordon will bring valuable insights into Orica’s growth strategy, manufacturing network and broader operations,” he said.
Mr Naylor will offer himself for election as a Director at the next Annual General Meeting in December 2022.
Gordon Naylor Biography
Beginning his career as an engineer in the car manufacturing industry, Mr Naylor then joined CSL, Australia’s leading global biotech company.
Over more than 30 years, Mr Naylor held a range of business and functional leadership roles in international environments within CSL including as Chief Financial Officer for five years. At the time of his retirement from CSL, he was President of Seqirus where he had led the three-year turnaround of that business into the global influenza vaccines leader.
Mr Naylor is an experienced corporate and people leader with strong business governance and deep analytical skills.
Mr Naylor is the Non-Executive Chair of Medical Developments International, a Fellow of ATSE and a Graduate of the AICD. He is tertiary qualified in engineering, computer science, accounting and management.